Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Seventy percent of breast cancers express the estrogen receptor (ER), and agents that target the ER are the mainstay of treatment. However, virtually all people with ER + breast cancer develop resistance to ER-directed agents in the metastatic setting. Beyond mutations in the ER itself, which occur...

Full description

Bibliographic Details
Main Authors: Nayar, Utthara, Cohen, Ofir, Kapstad, Christian, Cuoco, Michael S., Waks, Adrienne G., Wander, Seth A., Painter, Corrie, Freeman, Samuel, Persky, Nicole S., Marini, Lori, Helvie, Karla, Oliver, Nelly, Rozenblatt-Rosen, Orit, Ma, Cynthia X., Regev, Aviv, Winer, Eric P., Lin, Nancy U., Wagle, Nikhil
Other Authors: Massachusetts Institute of Technology. Department of Biology
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2020
Online Access:https://hdl.handle.net/1721.1/126730

Internet

https://hdl.handle.net/1721.1/126730

Similar Items